Catalyst Biosciences, Inc. (CBIO) News

Catalyst Biosciences, Inc. (CBIO): $7.67

0.21 (-2.65%)

POWR Rating

Component Grades








Add CBIO to Watchlist
Sign Up

Industry: Biotech




#199 of 355

in industry

Filter CBIO News Items

CBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CBIO News From Around the Web

Below are the latest news stories about CATALYST BIOSCIENCES INC that investors may wish to consider to help them evaluate CBIO as an investment opportunity.

Is Catalyst Biosciences (CBIO) Significantly Overvalued?

An Analysis of the Intrinsic Value and Future Prospects

Yahoo | August 23, 2023

Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months

In the last year, multiple insiders have substantially increased their holdings of Catalyst Biosciences, Inc...

Yahoo | April 3, 2023

12 Cheap Healthcare Stocks to Buy in 2023

In this piece, we will take a look at the twelve cheap healthcare stocks to buy in 2023. For more healthcare stocks, head on over to 5 Cheap Healthcare Stocks to Buy in 2023. The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades. Modern […]

Yahoo | March 29, 2023

Catalyst Biosciences Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”)

Yahoo | February 28, 2023

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21

Yahoo | December 27, 2022

Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences ( NASDAQ:CBIO ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.88m (loss narrowed...

Yahoo | November 16, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!